[{"orgOrder":0,"company":"ActualEyes","sponsor":"Arctic Vision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Rho-Associated Kinase-Human Corneal Endothelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ActualEyes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ActualEyes \/ Arctic Vision","highestDevelopmentStatusID":"4","companyTruncated":"ActualEyes \/ Arctic Vision"},{"orgOrder":0,"company":"SanBio","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Vandefitemcel","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SanBio \/ OcuMension Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SanBio \/ OcuMension Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : Under the Agreement, Celregen will have the exclusive right to develop, manufacture and commercialize CLS001 for bullous keratopathy in the Greater China region, including Mainland China, Hong Kong, Macau and Taiwan.

                          Product Name : CLS001

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 09, 2022

                          Lead Product(s) : CLS001

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Hangzhou Celregen Therapeutics

                          Deal Size : $100.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Lead Product(s) : Rho-Associated Kinase-Human Corneal Endothelial Cell

                          Therapeutic Area : Ophthalmology

                          Study Phase : Preclinical

                          Sponsor : Arctic Vision

                          Deal Size : $35.0 million

                          Deal Type : Licensing Agreement

                          Details : Arctic Vision will develop and market ActualEyes’ AE-101, for the treatment of corneal endothelial dysfunction in Greater China and South Korea. ARVN901 (AE-101) is a novel cell-injection therapy developed using cultured hCECs combined with a ROCK inhi...

                          Product Name : AE101

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 14, 2021

                          Lead Product(s) : Rho-Associated Kinase-Human Corneal Endothelial Cell

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Arctic Vision

                          Deal Size : $35.0 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : Ocumension obtains exclusive rights from SanBio to develop and commercialize SB623 and MSC2 in Greater China for ophthalmic indications.

                          Product Name : SB623

                          Product Type : Cell and Gene therapy

                          Upfront Cash : $6.0 million

                          March 31, 2020

                          Lead Product(s) : Vandefitemcel

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : OcuMension Therapeutics

                          Deal Size : $71.0 million

                          Deal Type : Agreement

                          blank